Table V.

Current^* clinical trials of anti-PD-1 and anti-PD-L1 blockades, including patients with metastatic melanoma.

Blockade/Tumor Type/Treatment	clinicaltrials.gov Identifier
Anti-PD-1
Melanoma specific
Nivolumab
Nivolumab monotherapy	NCT01621490
Nivolumab monotherapy vs nivolumab + ipilimumab vs ipilimumab monotherapy	NCT01844505 ^†
Nivolumab vs chemotherapy	NCT01721746,^† NCT010721772^†
Nivolumab + peptide^‡	NCT01176474, NCT01176461
Pembrolizumab
Pembrolizumab vs chemotherapy	NCT01704287
Pembrolizumab vs ipilimumab	NCT01866319
Pembrolizumab + pegIFN	NCT02112032
All/multiple tumors
Nivolumab
Nivolumab monotherapy	NCT00729664, NCT00836888
Nivolumab + anti-KIR	NCT01714739
Nivolumab + anti-LAG-3	NCT01968109
Nivolumab + IL-21	NCT01629758
Pembrolizumab
Pembrolizumab monotherapy	NCT01295827, NCT01848834
Pembrolizumab + 4-1BB agonist	NCT02179918
AMP-224 monotherapy	NCT01352884
AMP-514
AMP-514 monotherapy (MEDI-0680)	NCT02013804
AMP-514 + MEDI-4736	NCT02118337
CT-011⁶	NCT01386502 (w/d)
Anti-PD-L1
Melanoma specific
BMS-936559	NCT01455103 (w/d)
MEDI-4736 + dabrafenib/trametinib	NCT02027961
MPDL-3280A + vemurafenib	NCT01656642
All/multiple tumors
BMS-936559	NCT00729664
MEDI-4736
MEDI-4736 monotherapy	NCT01938612
MEDI-4736 + AMP-514	NCT02118337
MEDI-4736 + tremelimumab	NCT01975831
MPDL-3280A
MPDL-3280A monotherapy	NCT01375842
MPDL-3280A + bevacizumab	NCT01633970
MSB-0010718C	NCT01772004, NCT01943461

IL = interleukin; KIR = killer immunoglobulin-like receptor; LAG-3 = lymphocyte-activation gene 3; PD = programmed cell death protein; pegIFN = pegylated interferon; w/d = withdrawn.

Registered on clinicaltrials.gov as of July 7, 2014.

^†

Phase III.

^‡

The peptide vaccine was not included as a therapeutics, but to monitoring T-lymphocyte immune response in this dose-ranging nivolumab trial.